Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two Danish studies linking Novo Nordisk's popular diabetes drug Ozempic to a rare sight-threatening eye condition.

Novo's Ozempic faces scrutiny over potential link to rare eye disease

Eli Lilly

The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?

Novo Nordisk (NYSE:NVO), the Danish pharmaceutical company, plans to invest $1.2 billion in a new production facility in Odense, Denmark, focused on treatments for rare diseases. In an announcement, the company said the site will feature both a factory and a warehouse, designed to be modular and adaptable to support various rare disease products, including treatments for haemophilia.

Novo Nordisk plans $1.2bn Danish factory investment

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the production of rare disease drugs, it said on Monday.

Novo Nordisk to invest $1.2 bln in new plant in Denmark

Bagsværd, Denmark, 16 December 2024 – Today, Novo Nordisk announced plans to invest 8.5 billion Danish kroner to establish a completely new production facility in Odense, Denmark. The investment marks the first time in this century that Novo Nordisk breaks ground in Denmark by establishing a new production site.

Novo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark

Catalent

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.

Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say

Bagsværd, Denmark, 14 December 2024 — As of today, all regulatory closing conditions relating to the review of Novo Holdings A/S's pending acquisition of Catalent, Inc. (Catalent), including expiry of the timing agreement in the US, have been fulfilled. Catalent is a global contract development and manufacturing organisation headquartered in New Jersey (US). The parties are now free to close the transaction, as well as Novo Nordisk's subsequent acquisition of three Catalent manufacturing sites from Novo Holdings A/S.

Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close

NVO's reiterated FY2024 guidance and underwhelming FY2025 guidance in "the high teens" imply growth headwinds after the high-double digit growth observed in FY2023. This may be worsened by the uncertain regulation surrounding "drug compounders and companies that sell their products," pending further clarity in 2025. Even so, we believe that FY2025 is likely to be trough year, with FY2026 bringing forth robust numbers, assuming regulatory approvals for CagriSema.

Novo Nordisk's CagriSema May Trump Lilly's Zepbound - Buy This Dip

A recent cohort study conducted in Denmark and Norway reveals a potential link between the use of semaglutide for type 2 diabetes and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION).

Novo Nordisk's Ozempic Potentially Linked To Rare Vision Loss Risk, But Absolute Risk Is Low: Study

Novo Nordisk's diabetes drug, Ozempic, receives positive CHMP opinion in the EU for expanded use in T2D and CKD patients.

NVO Gets Positive CHMP Opinion in EU for Ozempic Expanded Use in CKD

Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in adults with Type 2 diabetes.

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.

Amazon

Carnival

Finding a good growth stock to buy these days isn't easy. Many that have been doing well are at sky-high valuations.

3 Growth Stocks That Can Be No-Brainer Buys in 2025

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the label of its diabetes drug Ozempic, the Danish drugmaker said in a statement on Thursday.

European drug regulator allows Novo to include reduction of kidney disease in Ozempic label

Bagsværd, Denmark, 12 December 2024 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly subcutaneous semaglutide) label to reflect data from the FLOW kidney outcomes trial. The FLOW trial assessed the risk reduction from Ozempic® therapy in chronic kidney disease-related events, including persistent ≥50% decline in estimated glomerular filtration rate (eGFR), onset of persistent eGFR

Novo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events

For the first time since I initiated coverage on the Danish weight loss treatments company Novo Nordisk earlier this year, it's now attractive enough to be upgraded to a Buy. Fears of a slump in its blockbuster weight loss treatment, Wegovy's sales in late September were assuaged with the company's Q3 2024 results. Market multiples for Novo Nordisk are also attractive now, especially with a forward P/E for 2025 at 28.3x.

Novo Nordisk: Just The Right Price (Rating Upgrade)

When it comes to weight loss drugs, Ozempic has become a phenomenon.

Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030

Novo Nordisk parent's huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Healthy Returns: A huge deal to boost Novo Nordisk's manufacturing is one step closer to closing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eikonizo Therapeutics, a biopharmaceutical company dedicated to developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases announced today that it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. In addition to supporting the development of Eikonizo's lead candidate, EKZ-102, a potential first-in-class, oral, CNS-penetrant, highly se.

Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development

Pfizer

Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Novo Nordisk (NVO). But which of these two stocks offers value investors a better bang for their buck right now?

PFE or NVO: Which Is the Better Value Stock Right Now?

The proposed buyout of contract drug manufacturer Catalent won't raise competition concerns, the European Commission said.

Novo Nordisk Just Got One Step Closer to Resolving Wegovy Supply Issue

Universal Health Realty Income Trust

Exxon Mobil

Berkshire Hathaway, Exxon Mobil, Novo Nordisk and Universal Health Realty Income Trust are included in this Analyst Blog.

The Zacks Analyst Blog Berkshire Hathaway, Exxon Mobil, Novo Nordisk and Universal Health Realty Income Trust

Vertex Pharmaceuticals

Growth. It's what most investors want more than anything else from their stocks. Some stocks can deliver more of it than others.

3 No-Brainer Growth Stocks to Buy in December

Bagsværd, Denmark, 6 December 2024 — Today, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. (Catalent), a global contract development and manufacturing organisation headquartered in New Jersey (US), as well as Novo Nordisk's subsequent acquisition of three manufacturing sites from Novo Holdings A/S.

The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings

Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker Catalent after EU regulators said they did not see any competition issues.

Novo Holdings' $16.5 bln Catalent buy wins EU antitrust approval

NVAX intends to use the payment from Novo to advance the development of its vaccine pipeline. The deal is expected to be closed by the end of this year.

News for Novo Nordisk Stock (NVO)